4'-Chlorodeschloroalprazolam

4'-Chlorodeschloroalprazolam is a triazolobenzodiazepine derivative which has been sold as a designer drug, presumably with sedative effects, first identified in Australia and the US in 2021,[1][2] and subsequently in Ireland.[3]

4'-Chlorodeschloroalprazolam
Identifiers
  • 6-(4-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC17H13ClN4
Molar mass308.77 g·mol−1
3D model (JSmol)
  • CC1=NN=C2N1C3=CC=CC=C3C(=NC2)C4=CC=C(C=C4)Cl
  • InChI=1S/C17H13ClN4/c1-11-20-21-16-10-19-17(12-6-8-13(18)9-7-12)14-4-2-3-5-15(14)22(11)16/h2-9H,10H2,1H3
  • Key:QZQFCOLCRXZSIK-UHFFFAOYSA-N

See also

edit

References

edit
  1. ^ Trigg S, Wells JM, McGann J, Bock S, Holman A, Harrison SM, et al. (September 2022). "The alprazolam analogue 4'-chloro deschloroalprazolam identified in seized capsules". Drug Testing and Analysis. 14 (9): 1672–1680. doi:10.1002/dta.3325. PMID 35666014.
  2. ^ Reber JD, Rodgers C, Ayala JL, Miller J, Stout P, Lee D (November 2023). "Interference of the novel designer benzodiazepine 4'-chloro-deschloroalprazolam with alprazolam analysis in toxicology and seized drug DUID casework". Journal of Analytical Toxicology. 47 (8): 680–684. doi:10.1093/jat/bkad047. PMID 37530763.
  3. ^ "New psychoactive substances - the current situation in Europe" (PDF). European Drug Report. European Union Drugs Agency (EUDA). 2024.